Search research articles
Contact Us
Filters
Showing results (41-50 of 55) with videos related to
Page
of 6
Sort By:
Pharmacogenomics
|
May 10, 2008
Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans
Nita A Limdi, Donna K Arnett, Joyce A Goldstein, et al.
The Journal of Biological Chemistry
|
November 19, 2003
Mouse liver CYP2C39 is a novel retinoic acid 4-hydroxylase. Its down-regulation offers a molecular basis for liver retinoid accumulation and fibrosis in aryl hydrocarbon receptor-null mice
Fausto Andreola, Graham P Hayhurst, Gang Luo, et al.
Molecular Pharmacology
|
April 23, 2004
Cloning, expression, and characterization of three new mouse cytochrome p450 enzymes and partial characterization of their fatty acid oxidation activities
Hong Wang, Yun Zhao, J Alyce Bradbury, et al.
Journal of the American Society of Nephrology : JASN
|
February 20, 2009
Kidney function influences warfarin responsiveness and hemorrhagic complications
Nita A Limdi, T Mark Beasley, Melissa F Baird, et al.
Transplantation
|
November 19, 2011
Associations of ABCB1 3435C>T and IL-10-1082G>A polymorphisms with long-term sirolimus dose requirements in renal transplant patients
Wai-Johnn Sam, Christine E Chamberlain, Su-Jun Lee, et al.
Transplantation
|
October 18, 2012
Associations of ABCB1 and IL-10 genetic polymorphisms with sirolimus-induced dyslipidemia in renal transplant recipients
Wai-Johnn Sam, Christine E Chamberlain, Su-Jun Lee, et al.
Journal of Clinical Pharmacology
|
April 28, 2006
Reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition
Su-Jun Lee, William J Jusko, Christine G Salaita, et al.
European Journal of Clinical Pharmacology
|
August 12, 2009
CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases
Melanie S Joy, Kimberly Dornbrook-Lavender, Joyce Blaisdell, et al.
Pharmacogenetics
|
July 31, 2004
Discovery of new potentially defective alleles of human CYP2C9
Joyce Blaisdell, Lucia F Jorge-Nebert, Sherry Coulter, et al.
Pharmacogenomics
|
October 16, 2008
VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans
Nita A Limdi, T Mark Beasley, Michael R Crowley, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 55) with videos related to
Sort By:
Page
of 6
Pharmacogenomics
|
May 10, 2008
Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans
Nita A Limdi, Donna K Arnett, Joyce A Goldstein, et al.
The Journal of Biological Chemistry
|
November 19, 2003
Mouse liver CYP2C39 is a novel retinoic acid 4-hydroxylase. Its down-regulation offers a molecular basis for liver retinoid accumulation and fibrosis in aryl hydrocarbon receptor-null mice
Fausto Andreola, Graham P Hayhurst, Gang Luo, et al.
Molecular Pharmacology
|
April 23, 2004
Cloning, expression, and characterization of three new mouse cytochrome p450 enzymes and partial characterization of their fatty acid oxidation activities
Hong Wang, Yun Zhao, J Alyce Bradbury, et al.
Journal of the American Society of Nephrology : JASN
|
February 20, 2009
Kidney function influences warfarin responsiveness and hemorrhagic complications
Nita A Limdi, T Mark Beasley, Melissa F Baird, et al.
Transplantation
|
November 19, 2011
Associations of ABCB1 3435C>T and IL-10-1082G>A polymorphisms with long-term sirolimus dose requirements in renal transplant patients
Wai-Johnn Sam, Christine E Chamberlain, Su-Jun Lee, et al.
Transplantation
|
October 18, 2012
Associations of ABCB1 and IL-10 genetic polymorphisms with sirolimus-induced dyslipidemia in renal transplant recipients
Wai-Johnn Sam, Christine E Chamberlain, Su-Jun Lee, et al.
Journal of Clinical Pharmacology
|
April 28, 2006
Reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition
Su-Jun Lee, William J Jusko, Christine G Salaita, et al.
European Journal of Clinical Pharmacology
|
August 12, 2009
CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases
Melanie S Joy, Kimberly Dornbrook-Lavender, Joyce Blaisdell, et al.
Pharmacogenetics
|
July 31, 2004
Discovery of new potentially defective alleles of human CYP2C9
Joyce Blaisdell, Lucia F Jorge-Nebert, Sherry Coulter, et al.
Pharmacogenomics
|
October 16, 2008
VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans
Nita A Limdi, T Mark Beasley, Michael R Crowley, et al.
Page
of 6